Ironwood Pharmaceuticals
IRWD
148 hedge funds and large institutions have $2.85B invested in Ironwood Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 49 increasing their positions, 46 reducing their positions, and 26 closing their positions.
114% more call options, than puts
Call options by funds: $27.3M | Put options by funds: $12.8M
21% more capital invested
Capital invested by funds: $2.35B → $2.85B (+$495M)
7% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 46
1% less funds holding
Funds holding: 149 → 148 (-1)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
2.3% less ownership
Funds ownership: 100.45% → 98.15% (-2.3%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$24.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$12.1M |
| 4 |
BlackRock
New York
|
+$10M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$87.2M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$21.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.4M |
| 4 |
SGA
Sector Gamma AS
Oslo,
Norway
|
-$12.3M |
| 5 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$12.1M |
IRWD Hedge Fund Activity: Q2 2018 in Review
148 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2018, worth a combined $2.85B — up 21% from $2.35B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of IRWD and 25 opened new positions — a net loss of 1 holder — while 46 trimmed existing stakes and 49 added.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $24.6M. The largest seller was BVF Inc, cutting an estimated $87.2M.
- 148 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2018, down from 149 in Q1 2018.
- Funds reported $2.85B of Ironwood Pharmaceuticals stock for Q2 2018, up 21% quarter-over-quarter.
- 25 funds opened new Ironwood Pharmaceuticals positions in Q2 2018 and 26 closed out, a net change of -1 holder.
- The largest Ironwood Pharmaceuticals buyer in Q2 2018 was Westfield Capital Management, an estimated $24.6M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2018 was BVF Inc, an estimated $87.2M sold.
Based on aggregated 13F filings for Q2 2018.